| NorthSea Therapeutics–SEVERAL: investment, 202001 financing round Series B €36m led by new investor VenBio |
2020-01-08 |
| PharmAkea–Galecto Biotech: investment, 202001– merger €na with new Galecto Inc in US with operational HQ in Copenhagen ANNOUNCED |
2020-01-07 |
| VectivBio–Novo Group: investment, 202001 1st financing round totalling $35m incl Novo Holdings |
2020-01-07 |
| VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. |
2020-01-07 |
| Integrated Biotherapeutics–Novo Group: investment, 202001 investment $3.9m in IBT Vaccines by Novo REPAIR Impact Fund |
2020-01-06 |
| Pharma Omnium–Novo Group: investment, 202001 investment €7m by Novo REPAIR Impact fund into Mutabilis |
2020-01-06 |
| Savara–SEVERAL: investment, 201912– private placement $26.8m (with potential total proceeds of $75m) to institutional investors leb by Bain Capital LS |
2019-12-20 |
| CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance |
2019-12-19 |
| Genmab–CureVac: mRNA-based antibody therapeutics, 201912– collab research + license agreem 5y $10m upfront using CureVac mRNA + Genmab Ab technologies |
2019-12-19 |
| BC Platforms–SEVERAL: investment, 201912 financing round Series C $15m led by Iqvia + incl Debiopharm Innovation Fund + Tesi |
2019-12-18 |
| Genomill Health–Avohoidon Tutkimussäätiö: investment, 201912 financing round incl co-investor Avohoidon Tutkimussäätiö |
2019-12-18 |
| Genomill Health–SEVERAL: investment, 201912 financing round led by Voima Ventures with Avohoidon Tutkimussäätiö |
2019-12-18 |
| Genomill Health–Voima Ventures: investment, 201912 financing round incl lead investor Voima Ventures |
2019-12-18 |
| BC Platforms–Scius Communications: public relations, 201912 supply service existent by Scius Communications |
2019-12-06 |
| Life & Brain–BC Platforms: genomic software tools, 201912– collab using BC Platforms solutions for genotyping services |
2019-12-06 |
| ECBF–SEVERAL: investment, 201911– European Circular Bioeconomy Fund aims to raise €250m incl up to €100m from EIB |
2019-11-29 |
| Novo Group–Optimum Strategic Communications: public relations, 201911 service existent by Optimum |
2019-11-26 |
| Ferring–Blackstone: investment, 201911– investment $400m by Blackstone Life Sciences in FerGene to develop + market nadofaragene firadenovec |
2019-11-25 |
| Veloxis Pharmaceuticals–Asahi Kasei: investment, 201911– recommended cash offer DKK 8.9b ($1.3b) by Asahi Kasei Pharma Denmark A/S |
2019-11-25 |
| Zelluna–Glycostem Therapeutics: cell therapy contract manufacturing, 201911– collab developm + supply of TCR-guided NK-cell therapies |
2019-11-19 |
| Dicerna Pharmaceuticals–Novo Group: investment, 201911 investment $50m by Novo in connection with r+d collab |
2019-11-18 |
| Novo Group–Dicerna Pharmaceuticals: RNAi therapeutics, 201911– collab r+d $175m upfront + milestones + investm RNAi drugs liver diseases using GalXC |
2019-11-18 |
| Gyros–Mesa Labs: investment, 201910 acquisition $180m in cash of Gyros Protein Technologies Holding AB by Mesa Laboratories Inc |
2019-10-31 |
| Disc Medicine–AbbVie: therapeutics antibodies, 201910– license €na ww excl to series of hemojuvelin antagonist MAbs from AbbVie |
2019-10-29 |
| Disc Medicine–Novo Group: investment, 201910 financing round Series A totalling $50m incl new + lead investor Novo Holdings A/S |
2019-10-29 |
| Disc Medicine–SEVERAL: investment, 201910 financing round Series A $50m led by Novo Holdings A/S |
2019-10-29 |
| OpGen–SEVERAL: investment, 201910 underwritten public offering $9.4m |
2019-10-23 |
| Encycle Therapeutics–Zealand Pharma: investment, 201910 acquisition of Encycle Therapeutics for up to $80m |
2019-10-22 |
| Bavarian Nordic–GSK: vaccines, 201910 acquisition up to €796m incl €301m upfront of manufacturing + global rights to Rabipur/RabAvert + Encepur by BN |
2019-10-21 |
| Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund |
2019-10-17 |
| Amarna Therapeutics–Flerie Invest: investment, 201910 financing round totalling €10m incl lead investor Flerie Invest AB + incl RVO innovation credit |
2019-10-16 |
| Amarna Therapeutics–Netherlands (govt): credit, 201910 financing round totalling €10m incl substantial innovation credit from RVO.nl |
2019-10-16 |
| Amarna Therapeutics–PERSON: investment, 201910 financing round totalling €10m incl existing + co-investor Pim Berger + incl RVO innovation credit |
2019-10-16 |
| Amarna Therapeutics–SEVERAL: investment, 201910 financing round €10m led by Flerie Invest AB + incl innovation credit from RVO.nl |
2019-10-16 |
| Novo Group–Bluebird Bio: gene therapy, 201910–202209 collab r+d 3y utilising megaTAL technology to develop hemophilia A gene therapies |
2019-10-09 |
| Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys |
2019-10-08 |
| Lundbeck–LeadXPro: drug discovery services, 201910– collab structural proteomics services using X-ray + cryo-EM for small molecule drug discovery |
2019-10-07 |
| Technical Univ Denmark–Inscripta: genome engineering technology, 201910 supply existent TUD NNFCB early customer Onyx Genome Engineering platform |
2019-10-01 |
| STipe Therapeutics–SEVERAL: investment, 201909 financing round Series A €20m co-led by Arix Bioscience + Novo Holdings |
2019-09-30 |
| Themis Bioscience–Hadean Ventures: investment, 201909 financing round Series D totalling €40m incl new + co-lead investor Hadean Ventures |
2019-09-18 |
| Themis Bioscience–SEVERAL: investment, 201909 financing round Series D €40m co-led by Farallon Capital + Hadean Ventures |
2019-09-18 |
| Alder Biopharmaceuticals–Lundbeck: investment, 201909–201910 acquisition tender offer in cash + CVRs up to $1.95b net of cash |
2019-09-16 |
| Orion Corp–Genedata: bioinformatics, 201909– supply license to Genedata Biologics as SaaS for large-molecule r+d to Orion Pharma |
2019-09-11 |
| Genmab–Tempus: AI-based drug discovery, 201909– strateg collab multi-year r+d targets + biomarker for personalised cancer drugs |
2019-09-09 |
| Sigrid Therapeutics–Axilium Capital: investment, 201909 financing round totalling $1.6m incl co-investor Axilium Capital |
2019-09-05 |
| Sigrid Therapeutics–Joyance Partners: investment, 201909 financing round totalling $1.6m incl co-lead investor Joyance Partners |
2019-09-05 |
| Sigrid Therapeutics–PERSON: investment, 201909 financing round totalling $1.6m incl co-investor Karsten Inde |
2019-09-05 |
| Sigrid Therapeutics–PERSON: investment, 201909 financing round totalling $1.6m incl co-lead investor Pär Gellerfors |
2019-09-05 |
| Sigrid Therapeutics–SEVERAL: investment, 201909 financing round $1.6m led by Joyance Partners + Pär Gellerfors |
2019-09-05 |
| Curetis–OpGen: investment, 201909– reverse merger with Curetis shareholders holding 72.5% of combined entity |
2019-09-04 |
| Protelux (RU)–Unibio: protein production from methane, 201908 collab existing buidling + operating plant for Uniprotein production in Russia |
2019-08-28 |
| Unibio–SEVERAL: investment, 201908 financing round $15m (£12.4m) from existing + new shareholders led by West Hill Capital |
2019-08-28 |
| Unibio–West Hill Capital: investment, 201908 financing round totalling $15m (£12.4m) incl lead investor West Hill Capital |
2019-08-28 |
| Nanovi–SEVERAL: investment, 201908 financing round DKK19m from existing investors |
2019-08-27 |
| Biotheus–Alligator Bioscience: therapeutic antibodies, 201908– license to Ab from Alligator-Gold library for bispecific molecules for Greater China |
2019-08-20 |
| Cytena–Cellink: investment, 201908 acquisition €30.25m of Cytena GmbH by Cellink AB |
2019-08-05 |
| Alizé Pharma–SEVERAL: investment, 201907 financing round Series A €67m of Alizé Pharma 3 led by LSP |
2019-07-31 |
| OncoImmunity–NEC: investment, 201907 acquisition by NEC and renamed NEC OncoImmunity AS |
2019-07-29 |
| Genmab–SEVERAL: investment, 201907 US IPO $581.6m with 28.5m+4.275m ADSs at $17.75/ADS with 10 ADSs/share at Nasdaq Global Select Market |
2019-07-22 |
| Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Genmab–Blink Biomedical: therapeutic antibodies, 201907– license to use CD47 Abs in DuoBodies $2.25m upfront + up to $200m per product plus royalties |
2019-07-12 |
| Nanoform–Notch Communications: public relations, 201907 service existent by Notch |
2019-07-10 |
| IGM Biosciences–Haldor Topsøe: investment, 201907 financing round Series C totalling $102m incl existing + founding investor Haldor Topsøe Holding A/S |
2019-07-08 |
| IGM Biosciences–SEVERAL: investment, 201907 financing round Series C $102m incl Redmile Group + Janus Henderson + Vivo Capital et al |
2019-07-08 |
| Danaher–Cobo Technologies: protein expression analysis, 201907– collab co-marketing PIPPR platform with SWATH Acquisition + Sciex TripleTOF 6600 |
2019-07-05 |
| Nanoform–SEVERAL: investment, 201907 private placement €10m incl Ilmarinen Mutual Pension Insurance + Mandatum Life Insurance |
2019-07-03 |
| ExpreS2ion Biotech–ERS Genomics: CRISPR technology, 201907– license non-excl €na for use + commercialisation of products from ERS Genomics |
2019-07-01 |
| Yahong Meditech–Photocure: Cevira®, 201907– license ww developm + commercialisation to Asieris up to $250m milestones + royalties |
2019-07-01 |
| Oncopeptides–SEVERAL: investment, 201906 directed share issue SEK727m ($78m) of 5.015m new shares at SEK145/share |
2019-06-27 |
| Sanifit–Lundbeck: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Lundbeckfonden Ventures |
2019-06-26 |
| UmanDiagnostics–Quanterix: investment, 201906–201907 acquisition $16m in cash + $6.5m in common stock |
2019-06-26 |
| Forendo Pharma–Vesalius Biocapital: investment, 201906 existent investment of Vesalius Biocapital III fund |
2019-06-25 |
| Sword Health–Vesalius Biocapital: investment, 201906 existent investment of Vesalius Biocapital III fund |
2019-06-25 |
| Karolinska Institutet–BGI: DNA sequencing, 201906– collab using DNBSEQ techn for shotgun metagenomics data from microbiome biobank MGI Tech |
2019-06-20 |
| Spero Therapeutics–Novo Group: investment, 201906– direct offering common stock up to $10m in two tranches of $5m to Novo REPAIR Fund |
2019-06-13 |
| JnJ–Genmab: antibody cancer drug, 201906– collab + excl ww license + option agreem for HexaBody-CD38 monoclonal antibody |
2019-06-11 |
| Merck (US)–Agilent: molecular companion diagnostics, 201906 collab existent developm of PD-L1 IHC 22CR pharmDx for use with Keytruda |
2019-06-11 |
| Saga Diagnostics–Fårö Capital: investment, financing round totalling SEK40m (€3.7m) incl existing + co-investor Fårö Capital |
2019-06-11 |
| Saga Diagnostics–Gunnar Nilsson Cancer Foundation: investment, financing round totalling SEK40m (€3.7m) incl existing + co-investor GNCF |
2019-06-11 |
| Saga Diagnostics–Hadean Ventures: investment, financing round totalling SEK40m (€3.7m) incl new + lead investor Hadean Ventures |
2019-06-11 |
| Saga Diagnostics–SEVERAL: investment, 201906 financing round SEK40m (€3.7m) led by new investor Hadean Ventures |
2019-06-11 |
| Yingsheng Biotechnology–Biotage: clinical mass spectrometry, 201906– collab strategic + OEM sale in China by Shandong Yingsheng Biotechnology |
2019-06-04 |
| Oxford BioMedica–Novo Group: investment, 201905–201906 investment £45.3m + optional £8.2m with 6.6m+1.2m new shares at £6.9/share |
2019-05-28 |
| Fujifilm–Genovis: enzymes, 201905– collab distribution of SmartEnzymes in Japan + Taiwan + Singapore by Fujifilm Wako Pure Chemical |
2019-05-16 |
| Symphogen–SEVERAL: investment, 201905– capital increase up to DKK572m incl DKK182m debt conversion from existing shareholders |
2019-05-15 |
| Therachon–Novo Group: investment, 201905 existing investor Novo Holdings |
2019-05-08 |
| Abide Therapeutics–Lundbeck: investment, 201905 acquisition $250m upfront + $150m milestones of Abide by Lundbeck |
2019-05-06 |
| United States (govt)–Cobo Technologies: genome editing, 201904– collab Cobo beomes member of NIST Genome Editing Consortium |
2019-04-15 |
| Gilead–Novo Group: drug development, 201904– collab clinical research for NASH combining semaglutide + cilofexor + firsocostat Novo Nordisk |
2019-04-12 |
| Probiodrug–SEVERAL: investment, 201904 private placement €8.2m net €7.65m with 4.1m new shares at €2m led by Claus Christiansen et al. |
2019-04-09 |
| Gesynta Pharma–SEVERAL: investment, 201904 financing round €6m led by Industrifonden + incl group of private life science investors |
2019-04-04 |
| Gesynta Pharma–Sweden (govt): investment, 201904 financing round totalling €6m incl lead investor Industrifonden |
2019-04-04 |
| Chr Hansen–Lonza: live biotherapeutics, 201904– collab establishment 50/50 joint venture for developing + manufacturing microbiome treatments |
2019-04-02 |
| Cytena–High-Tech Gründerfonds: investment, 201903 financing round Series A totalling €3.m incl HTGF + two private investors |
2019-03-26 |
| Cytena–SEVERAL: investment, 201903 financing round Series A €3m from HTGF + two private investors |
2019-03-26 |
| Lundbeck–Enamine: chemical compound libraries, 201903– supply expansion discovery chemistry services by Enamine |
2019-03-26 |
| Verona Pharma–Novo Group: investment, 201903 existent investment Novo Holdings owns 11.76% shareholding in Verona Pharma plc |
2019-03-21 |
| Biogen–Fujifilm: biologics contract manfuacturing, 201903– supply manufacturing of biologicals for Biogen incl Tysabri |
2019-03-12 |
![[LSS] Life-Sciences-Scandinavia.com - The Scandinavian Life Sciences Web Portal](/images/basics/lss-life-sciences-scandinavia-portal-logo-2019.png){kind=logo}
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lsus-life-sciences-usa-com.jpg)
Date
![Picture [iito] LSUS iitoLifeScience Transatlantic Life Sciences 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
